Vanguard Global Advisers’s Actuate Therapeutics ACTU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$3.98K Hold
5,102
– – ﹤0.01% 3614
2026
Q2
$7.81K Hold
5,102
– – ﹤0.01% 3514
2026
Q1
$14K Buy
+5,102
New +$21.1K ﹤0.01% 3411

Other funds holding ACTU

Vanguard Global Advisers's ACTU Position: Q3 2026 in Review

Vanguard Global Advisers held its Actuate Therapeutics (ACTU) position steady in Q3 2026 at 5,102 shares worth $3.98K. The position accounts for ﹤0.01% of the portfolio, ranked #3614.

Vanguard Global Advisers first reported a position in ACTU in Q1 2026 and has held it in 3 quarters since. The position peaked at $14K in Q1 2026. 33 funds tracked by Wall St. Rank hold ACTU as of Q3 2026.

  • Vanguard Global Advisers held 5,102 shares of Actuate Therapeutics worth $3.98K as of Q3 2026.
  • Vanguard Global Advisers left its Actuate Therapeutics share count unchanged in Q3 2026.
  • Actuate Therapeutics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3614 holding.
  • Vanguard Global Advisers first reported a position in Actuate Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Actuate Therapeutics position peaked at $14K in Q1 2026.
  • 33 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.